Monoamine Oxidase as a Potential Biomarker of the Efficacy of Treatment of Mental Disorders

Abstract The review summarizes the results of our own studies and published data on the biological markers of psychiatric disorders, with special emphasis on the activity of platelet monoamine oxidase. Pharmacotherapy studies in patients with the mixed anxiety-depressive disorder and first episode of schizophrenia have shown that the activity of platelet monoamine oxidase could serve as a potential biomarker of the efficacy of therapeutic interventions in these diseases.

Download Full-text

Monoamine Oxidase and Semi Carbazide-Sensitive Amine Oxidase in Pathogenetic Mechanisms of First Episode of Schizophrenia

Biomedical Journal of Scientific & Technical Research ◽

10.26717/bjstr.2019.23.003856 ◽

2019 ◽

Vol 23 (1) ◽

Author(s):

Uzbekov M

Keyword(s):

Monoamine Oxidase ◽

Amine Oxidase ◽

First Episode ◽

Pathogenetic Mechanisms ◽

First Episode Of Schizophrenia

Download Full-text

The first-episode of schizophrenia: a challenge for treatment

European Psychiatry ◽

10.1016/s0924-9338(03)00076-2 ◽

2002 ◽

Vol 17 (S4) ◽

pp. 371s-375s ◽

Cited By ~ 4

Author(s):

W.W. Fleischhacker

Keyword(s):

Relapse Prevention ◽

Public Perception ◽

Young Patients ◽

Chronically Ill ◽

Negative Influence ◽

First Episode ◽

Published Data ◽

Main Challenge ◽

Treatment Alliance ◽

First Episode Of Schizophrenia

SummaryFor young people experiencing a first-episode of schizophrenia, the first and most important matter to be attended to, once the diagnosis of schizophrenia has been made and patients have entered the care system, is to establish a treatment alliance. The next step is to conceive an individually tailored treatment programme (non-pharmacological as well as pharmacological). The use of antipsychotic drugs needs to be carefully discussed with both patients and families, as medication tends to have a poor public perception. Maintaining treatment is vitally important in terms of relapse prevention, but people who suffer a first-episode tend to terminate treatment early. Patients often discontinue their medication because of side-effects, although a number of other factors can also exert a negative influence on the continuous intake of medication. Among others, these include insufficient information provided to patients and significant others as well as lack of insight and problems in the doctor-patient-relationship. The published data indicate that the outcome of treatment is better for younger patients in a first-episode of schizophrenia than it is for patients who are more chronically ill. However, young patients are much more sensitive to compliance problems than older patients. The main challenge in this phase of the illness is therefore to convince patients that maintenance treatment is necessary in order to assure the best possible outcome.

Download Full-text

Review paper. Neuropsychological dimension of schizophrenia - evaluation possibilities and therapeutic implications

Current Problems of Psychiatry ◽

10.1515/cpp-2017-0005 ◽

2017 ◽

Vol 18 (1) ◽

pp. 51-61

Author(s):

Agata Makarewicz ◽

Hanna Karakuła-Juchnowicz ◽

Łukasz Łobejko

Keyword(s):

Early Intervention ◽

Cognitive Dysfunction ◽

Cognitive Disorders ◽

Therapeutic Interventions ◽

First Episode ◽

Spatial Skills ◽

Prodromal Phase ◽

Therapeutic Implications ◽

Increased Risk ◽

First Episode Of Schizophrenia

Abstract Introduction: In the last decades, researchers' attention has been focused on cognitive dysfunction in schizophrenia. Numerous studies indicate the existence of neurodegenerative deficits in schizophrenia including, but not limited to, motor functions, learning and memory, executive functions, attention, language, spatial skills and general intelligence. Method: A review of available literature on the topic of the past two decades, available in the Pubmed, EBSCO, SCOPUS databases has been made using the keywords: schizophrenia, cognition, early intervention. Results: Cognitive dysfunction is an important feature of the prodromal phase and the first episode of schizophrenia. Researchers have thus proposed to initiate early therapeutic interventions for people with so-called risky mental conditions. The article includes the reference to research on neurocognitive disorders essence in schizophrenia, the definition and review of methods used to identify specific cognitive deficits and issues related to risk of developing psychosis and early therapeutic intervention in high-risk states. Conclusions: Researchers report the importance of detecting cognitive disorders in the early stages of schizophrenia. This broadens the range of therapeutic interventions and enables early intervention in the increased risk of psychosis.

Download Full-text